Ankylosing Spondylitis

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 57624 Experts worldwide ranked by ideXlab platform

Jia Zhou - One of the best experts on this subject based on the ideXlab platform.

  • quantitative metagenomics reveals unique gut microbiome biomarkers in Ankylosing Spondylitis
    Genome Biology, 2017
    Co-Authors: Chengping Wen, Zhijun Zheng, Tiejuan Shao, Lin Liu, Zhijun Xie, Wendi Zhong, Yongsheng Fan, Linshuang Zhang, Jia Zhou, Shunfeng Cai
    Abstract:

    The assessment and characterization of the gut microbiome has become a focus of research in the area of human autoimmune diseases. Ankylosing Spondylitis is an inflammatory autoimmune disease and evidence showed that Ankylosing Spondylitis may be a microbiome-driven disease. To investigate the relationship between the gut microbiome and Ankylosing Spondylitis, a quantitative metagenomics study based on deep shotgun sequencing was performed, using gut microbial DNA from 211 Chinese individuals. A total of 23,709 genes and 12 metagenomic species were shown to be differentially abundant between Ankylosing Spondylitis patients and healthy controls. Patients were characterized by a form of gut microbial dysbiosis that is more prominent than previously reported cases with inflammatory bowel disease. Specifically, the Ankylosing Spondylitis patients demonstrated increases in the abundance of Prevotella melaninogenica, Prevotella copri, and Prevotella sp. C561 and decreases in Bacteroides spp. It is noteworthy that the Bifidobacterium genus, which is commonly used in probiotics, accumulated in the Ankylosing Spondylitis patients. Diagnostic algorithms were established using a subset of these gut microbial biomarkers. Alterations of the gut microbiome are associated with development of Ankylosing Spondylitis. Our data suggest biomarkers identified in this study might participate in the pathogenesis or development process of Ankylosing Spondylitis, providing new leads for the development of new diagnostic tools and potential treatments.

  • Quantitative metagenomics reveals unique gut microbiome biomarkers in Ankylosing Spondylitis
    Genome Biology, 2017
    Co-Authors: Chengping Wen, Zhijun Zheng, Tiejuan Shao, Lin Liu, Zhijun Xie, Wendi Zhong, Yongsheng Fan, Linshuang Zhang, Emmanuelle Le Chatelier, Jia Zhou
    Abstract:

    Background: The assessment and characterization of the gut microbiome has become a focus of research in the area of human autoimmune diseases. Ankylosing Spondylitis is an inflammatory autoimmune disease and evidence showed that Ankylosing Spondylitis may be a microbiome-driven disease. Results: To investigate the relationship between the gut microbiome and Ankylosing Spondylitis, a quantitative metagenomics study based on deep shotgun sequencing was performed, using gut microbial DNA from 211 Chinese individuals. A total of 23,709 genes and 12 metagenomic species were shown to be differentially abundant between Ankylosing Spondylitis patients and healthy controls. Patients were characterized by a form of gut microbial dysbiosis that is more prominent than previously reported cases with inflammatory bowel disease. Specifically, the Ankylosing Spondylitis patients demonstrated increases in the abundance of Prevotella melaninogenica, Prevotella copri, and Prevotella sp. C561 and decreases in Bacteroides spp. It is noteworthy that the Bifidobacterium genus, which is commonly used in probiotics, accumulated in the Ankylosing Spondylitis patients. Diagnostic algorithms were established using a subset of these gut microbial biomarkers. Conclusions: Alterations of the gut microbiome are associated with development of Ankylosing Spondylitis. Our data suggest biomarkers identified in this study might participate in the pathogenesis or development process of Ankylosing Spondylitis, providing new leads for the development of new diagnostic tools and potential treatments.

Shih-wei Lai - One of the best experts on this subject based on the ideXlab platform.

  • Diabetes mellitus in Ankylosing Spondylitis.
    Annals of the Rheumatic Diseases, 2019
    Co-Authors: Kuan-fu Liao, Yu-hung Kuo, Shih-wei Lai
    Abstract:

    Ankylosing Spondylitis is a systemic inflammatory disease which always influences the spine joints. The association between Ankylosing Spondylitis and multiple systemic comorbidities has been well assessed.1 2 Recently, one meta-analysis conducted by Mathieu et al published in Annals of the Rheumatic Diseases reported that persons with Ankylosing Spondylitis were significantly associated with increased risks of myocardial infarction and stroke when compared with controls (risk ratio=1.44 for myocardial infarction, and risk ratio=1.37 for stroke).3 Mathieu et al ’s research is well performed and informative to the readers. Diabetes mellitus is a well-established risk factor for myocardial infarction and stroke. One cross-sectional study reported that 13.64% of persons with Ankylosing Spondylitis had diabetes mellitus.4 We make a rational hypothesis that diabetes mellitus could be involved in the association between Ankylosing

  • Association between Ankylosing Spondylitis and venous thromboembolism.
    Annals of the rheumatic diseases, 2019
    Co-Authors: Shih-wei Lai
    Abstract:

    Ankylosing Spondylitis is a type of arthritis that commonly affects the joints of the spine. The relationship between Ankylosing Spondylitis and other diseases has been extensively explored.1 2 Recently, a cohort study in Canada conducted by Avina-Zubieta et al published in Annals of Rheumatic Diseases disclosed that people with Ankylosing Spondylitis were at higher risk of venous thromboembolism compared with people without Ankylosing Spondylitis (HR 1.53, 95% CI 1.16 to 2.01).3 Avina-Zubieta et al ’s study is well performed and is informative to the researchers. Some of my views are shared with the readers as follows. First, the overall …

Chengping Wen - One of the best experts on this subject based on the ideXlab platform.

  • quantitative metagenomics reveals unique gut microbiome biomarkers in Ankylosing Spondylitis
    Genome Biology, 2017
    Co-Authors: Chengping Wen, Zhijun Zheng, Tiejuan Shao, Lin Liu, Zhijun Xie, Wendi Zhong, Yongsheng Fan, Linshuang Zhang, Jia Zhou, Shunfeng Cai
    Abstract:

    The assessment and characterization of the gut microbiome has become a focus of research in the area of human autoimmune diseases. Ankylosing Spondylitis is an inflammatory autoimmune disease and evidence showed that Ankylosing Spondylitis may be a microbiome-driven disease. To investigate the relationship between the gut microbiome and Ankylosing Spondylitis, a quantitative metagenomics study based on deep shotgun sequencing was performed, using gut microbial DNA from 211 Chinese individuals. A total of 23,709 genes and 12 metagenomic species were shown to be differentially abundant between Ankylosing Spondylitis patients and healthy controls. Patients were characterized by a form of gut microbial dysbiosis that is more prominent than previously reported cases with inflammatory bowel disease. Specifically, the Ankylosing Spondylitis patients demonstrated increases in the abundance of Prevotella melaninogenica, Prevotella copri, and Prevotella sp. C561 and decreases in Bacteroides spp. It is noteworthy that the Bifidobacterium genus, which is commonly used in probiotics, accumulated in the Ankylosing Spondylitis patients. Diagnostic algorithms were established using a subset of these gut microbial biomarkers. Alterations of the gut microbiome are associated with development of Ankylosing Spondylitis. Our data suggest biomarkers identified in this study might participate in the pathogenesis or development process of Ankylosing Spondylitis, providing new leads for the development of new diagnostic tools and potential treatments.

  • Quantitative metagenomics reveals unique gut microbiome biomarkers in Ankylosing Spondylitis
    Genome Biology, 2017
    Co-Authors: Chengping Wen, Zhijun Zheng, Tiejuan Shao, Lin Liu, Zhijun Xie, Wendi Zhong, Yongsheng Fan, Linshuang Zhang, Emmanuelle Le Chatelier, Jia Zhou
    Abstract:

    Background: The assessment and characterization of the gut microbiome has become a focus of research in the area of human autoimmune diseases. Ankylosing Spondylitis is an inflammatory autoimmune disease and evidence showed that Ankylosing Spondylitis may be a microbiome-driven disease. Results: To investigate the relationship between the gut microbiome and Ankylosing Spondylitis, a quantitative metagenomics study based on deep shotgun sequencing was performed, using gut microbial DNA from 211 Chinese individuals. A total of 23,709 genes and 12 metagenomic species were shown to be differentially abundant between Ankylosing Spondylitis patients and healthy controls. Patients were characterized by a form of gut microbial dysbiosis that is more prominent than previously reported cases with inflammatory bowel disease. Specifically, the Ankylosing Spondylitis patients demonstrated increases in the abundance of Prevotella melaninogenica, Prevotella copri, and Prevotella sp. C561 and decreases in Bacteroides spp. It is noteworthy that the Bifidobacterium genus, which is commonly used in probiotics, accumulated in the Ankylosing Spondylitis patients. Diagnostic algorithms were established using a subset of these gut microbial biomarkers. Conclusions: Alterations of the gut microbiome are associated with development of Ankylosing Spondylitis. Our data suggest biomarkers identified in this study might participate in the pathogenesis or development process of Ankylosing Spondylitis, providing new leads for the development of new diagnostic tools and potential treatments.

Shunfeng Cai - One of the best experts on this subject based on the ideXlab platform.

  • quantitative metagenomics reveals unique gut microbiome biomarkers in Ankylosing Spondylitis
    Genome Biology, 2017
    Co-Authors: Chengping Wen, Zhijun Zheng, Tiejuan Shao, Lin Liu, Zhijun Xie, Wendi Zhong, Yongsheng Fan, Linshuang Zhang, Jia Zhou, Shunfeng Cai
    Abstract:

    The assessment and characterization of the gut microbiome has become a focus of research in the area of human autoimmune diseases. Ankylosing Spondylitis is an inflammatory autoimmune disease and evidence showed that Ankylosing Spondylitis may be a microbiome-driven disease. To investigate the relationship between the gut microbiome and Ankylosing Spondylitis, a quantitative metagenomics study based on deep shotgun sequencing was performed, using gut microbial DNA from 211 Chinese individuals. A total of 23,709 genes and 12 metagenomic species were shown to be differentially abundant between Ankylosing Spondylitis patients and healthy controls. Patients were characterized by a form of gut microbial dysbiosis that is more prominent than previously reported cases with inflammatory bowel disease. Specifically, the Ankylosing Spondylitis patients demonstrated increases in the abundance of Prevotella melaninogenica, Prevotella copri, and Prevotella sp. C561 and decreases in Bacteroides spp. It is noteworthy that the Bifidobacterium genus, which is commonly used in probiotics, accumulated in the Ankylosing Spondylitis patients. Diagnostic algorithms were established using a subset of these gut microbial biomarkers. Alterations of the gut microbiome are associated with development of Ankylosing Spondylitis. Our data suggest biomarkers identified in this study might participate in the pathogenesis or development process of Ankylosing Spondylitis, providing new leads for the development of new diagnostic tools and potential treatments.

Zhijun Zheng - One of the best experts on this subject based on the ideXlab platform.

  • quantitative metagenomics reveals unique gut microbiome biomarkers in Ankylosing Spondylitis
    Genome Biology, 2017
    Co-Authors: Chengping Wen, Zhijun Zheng, Tiejuan Shao, Lin Liu, Zhijun Xie, Wendi Zhong, Yongsheng Fan, Linshuang Zhang, Jia Zhou, Shunfeng Cai
    Abstract:

    The assessment and characterization of the gut microbiome has become a focus of research in the area of human autoimmune diseases. Ankylosing Spondylitis is an inflammatory autoimmune disease and evidence showed that Ankylosing Spondylitis may be a microbiome-driven disease. To investigate the relationship between the gut microbiome and Ankylosing Spondylitis, a quantitative metagenomics study based on deep shotgun sequencing was performed, using gut microbial DNA from 211 Chinese individuals. A total of 23,709 genes and 12 metagenomic species were shown to be differentially abundant between Ankylosing Spondylitis patients and healthy controls. Patients were characterized by a form of gut microbial dysbiosis that is more prominent than previously reported cases with inflammatory bowel disease. Specifically, the Ankylosing Spondylitis patients demonstrated increases in the abundance of Prevotella melaninogenica, Prevotella copri, and Prevotella sp. C561 and decreases in Bacteroides spp. It is noteworthy that the Bifidobacterium genus, which is commonly used in probiotics, accumulated in the Ankylosing Spondylitis patients. Diagnostic algorithms were established using a subset of these gut microbial biomarkers. Alterations of the gut microbiome are associated with development of Ankylosing Spondylitis. Our data suggest biomarkers identified in this study might participate in the pathogenesis or development process of Ankylosing Spondylitis, providing new leads for the development of new diagnostic tools and potential treatments.

  • Quantitative metagenomics reveals unique gut microbiome biomarkers in Ankylosing Spondylitis
    Genome Biology, 2017
    Co-Authors: Chengping Wen, Zhijun Zheng, Tiejuan Shao, Lin Liu, Zhijun Xie, Wendi Zhong, Yongsheng Fan, Linshuang Zhang, Emmanuelle Le Chatelier, Jia Zhou
    Abstract:

    Background: The assessment and characterization of the gut microbiome has become a focus of research in the area of human autoimmune diseases. Ankylosing Spondylitis is an inflammatory autoimmune disease and evidence showed that Ankylosing Spondylitis may be a microbiome-driven disease. Results: To investigate the relationship between the gut microbiome and Ankylosing Spondylitis, a quantitative metagenomics study based on deep shotgun sequencing was performed, using gut microbial DNA from 211 Chinese individuals. A total of 23,709 genes and 12 metagenomic species were shown to be differentially abundant between Ankylosing Spondylitis patients and healthy controls. Patients were characterized by a form of gut microbial dysbiosis that is more prominent than previously reported cases with inflammatory bowel disease. Specifically, the Ankylosing Spondylitis patients demonstrated increases in the abundance of Prevotella melaninogenica, Prevotella copri, and Prevotella sp. C561 and decreases in Bacteroides spp. It is noteworthy that the Bifidobacterium genus, which is commonly used in probiotics, accumulated in the Ankylosing Spondylitis patients. Diagnostic algorithms were established using a subset of these gut microbial biomarkers. Conclusions: Alterations of the gut microbiome are associated with development of Ankylosing Spondylitis. Our data suggest biomarkers identified in this study might participate in the pathogenesis or development process of Ankylosing Spondylitis, providing new leads for the development of new diagnostic tools and potential treatments.